Sars in short
SARS (Severe Acute Respiratory Syndrome) is a viral respiratory illness caused by a coronavirus (SARS-CoV), first identified in southern China in 2002-2003. It spread to over 26 countries, infecting ~8,000 people and killing ~774 (about 10% mortality rate). The outbreak was contained by mid-2003 through isolation and quarantine measures, with no sustained transmission since.
Key facts:
- Cause: SARS-CoV (a betacoronavirus), likely originating in bats, with civet cats as an intermediate host
- Spread: Droplet transmission (coughing, sneezing), close contact
- Symptoms: Fever, chills, headache, muscle aches, dry cough, progressing to pneumonia in severe cases
- Incubation: 2-7 days (up to 10)
- Diagnosis: PCR testing, serology, chest X-ray (bilateral infiltrates)
- Treatment: Supportive care; ribavirin and steroids were used but with limited proven benefit
- Containment: No approved vaccine or specific antiviral; controlled via isolation, contact tracing, and quarantine
- Legacy: SARS led to major reforms in global pandemic preparedness, and research on SARS-CoV directly accelerated the rapid response to SARS-CoV-2 (COVID-19) in 2020
SARS is distinct from MERS (Middle East Respiratory Syndrome, caused by MERS-CoV) and from COVID-19 (SARS-CoV-2), though all three belong to the same coronavirus family.
Treatment drugs
Finding Sources
Searching PubMed
SARS-CoV treatment antiviral drugs
Here is a concise breakdown of drugs used or studied for SARS (2002-2003 outbreak):
SARS Treatment Drugs
1. Ribavirin
- Most widely used during the outbreak
- Broad-spectrum antiviral; inhibits viral RNA synthesis
- Used in combination with steroids
- Evidence: Inconsistent - some studies showed benefit, others showed toxicity (hemolytic anemia, liver toxicity) with little proven efficacy
- Now considered largely ineffective against SARS-CoV in retrospect
2. Corticosteroids (e.g., Methylprednisolone)
- Used to reduce lung inflammation and prevent cytokine storm
- Common combination: ribavirin + corticosteroids
- Benefit was debated - may suppress immune clearance of virus if given too early
- Still used empirically in severe pneumonia/ARDS cases
3. Lopinavir/Ritonavir (Kaletra)
- HIV protease inhibitor combination
- Showed in vitro activity against SARS-CoV
- A Hong Kong study (Chu et al.) found lopinavir/ritonavir + ribavirin reduced mortality and intubation rates compared to ribavirin alone
- As Goldman-Cecil Medicine notes: "treatment of SARS with lopinavir plus ritonavir resulted in lower mortality compared" to controls
- Later studied for SARS-CoV-2 (COVID-19) with disappointing results
4. Interferon (IFN-alpha, IFN-beta)
- Antiviral cytokines that inhibit coronavirus replication
- Used in some patients, particularly in China and Canada
- Combined with ribavirin in some protocols
- Limited clinical data; shown to have in vitro activity
5. Convalescent Plasma
- Plasma from recovered SARS patients given to severe cases
- Some observational evidence of benefit (earlier discharge in Hong Kong)
- Not widely validated in controlled trials
6. Intravenous Immunoglobulin (IVIG)
- Used in some severe cases
- Mechanism: passive immunity; also anti-inflammatory
- Evidence limited and anecdotal
Bottom Line
| Drug | Role | Evidence |
|---|---|---|
| Ribavirin | Antiviral | Weak; significant toxicity |
| Corticosteroids | Anti-inflammatory | Mixed; risk of immunosuppression |
| Lopinavir/Ritonavir | Antiviral | Modest benefit in one key study |
| Interferon | Antiviral | Mostly in vitro; limited clinical data |
| Convalescent plasma | Passive immunity | Small observational benefit |
| IVIG | Immune modulation | Anecdotal |
No treatment was ever formally approved for SARS. The outbreak was controlled by public health measures, not drugs. All treatment was off-label and empirical. - Goldman-Cecil Medicine
This is a shared conversation. Sign in to Orris to start your own chat.